Page 44 - MemoriaER-Eng

HORIZONTAL PROGRAMMES

Group
Application No.
Title

National

GSE24.2 peptide derivatives to treat diseases caused
U757
P201331573
by oxidative stress and damage to DNA

Biodegradable bionanoparticles for the release of the
U757
P201330131
GSE24-2 peptide, method for obtaining same and use

thereof
International

U756
PCT/ES2013/070592
New animal achromatopsia model

U757
PCT/ES2013/070581
Release of substances into senescent cells

The primary activities for promoting the Transfer performed by CIBERER are the fo-

llowing:

Development of tools for transfer processes

First, CIBERER continues providing advisory services relating to intellectual property

and other aspects relating to the transfer. This task was coordinated by Scientific Ma-
nagement with the support of the company Clarke, Modet & Co. Investigators chan-

neled all their queries relating to the protection of R&D&I activities generated while

carrying out their projects, and received guidance and support about applying good
practices in management the measures for protecting project results. The following

situations in which Clarke, Modet & Co. offered support to CIBERER groups in 2013
stand out: evaluation of the patentability of certain diagnostic methods, different que-

ries about creating a spin-off in the biomedical field and aspects relating to marketing

research results, queries about an orphan drug or drafting a CIBERER patent. They
have also provided advisory services to the department of managers by evaluating the

portfolio patents in which CIBERER participates to offer an estimate/forecast of expen-

ses resulting from said patents.

We have also worked to identify and assess goods and services of the different CIBE-
RER groups with transfer potential.

CIBERER is a full member of ASEBIO (Spanish Association of Biocompanies). In 2013,

CIBERER continued its activity within the Innovate Drug group, the specific Rare Di-
seases and Advanced Therapies subgroups, as well as in the Molecular Diagnosis Work

Group, actively participating in the different meetings. Since 2011, CIBERER has also
13
been an associate member of BIOVAL (Bioregion of the Community of Valencia). AND 20
since the year 2013 is partner collaborator of the Technologies Medical and Health T
R
Innovation (ITEMAS) Platform. The ITEMAS Platform seeks to encourage innovation PO
E
in health technology as a fundamental tool to make the National Health System more L R
sustainable, supporting the development of the innovative culture necessary to facili- A
NU
tate integrating the science-industry system in the field of medical technology.
N
A
/
ER
ER
B
CI

44